Table 1.
Summary of Study Participants
| Case | Age (years) | Sex | PMI (hour) | % Inclusions Ub+/Syn+ |
|---|---|---|---|---|
| DLB-1 | 66 | M | 11 | 96 |
| DLB-2 | 75 | F | 6 | 91 |
| DLB-3 | 79 | M | 20.5 | 79 |
| DLB-4 | 69 | F | 12 | 87 |
| DLB-5 | 71 | M | 9 | 89 |
| DLB-6 | 90 | F | 5 | * |
| MSA-1 | 55 | M | 7 | 53 |
| MSA-2 | 67 | F | 5 | 85 |
| MSA-3 | 60 | F | 10.5 | 96 |
| MSA-4 | 43 | M | 20 | 36 |
| MSA-5 | 79 | M | 16 | 19 |
| MSA-6 | 65 | M | 43 | 49 |
| MSA-7 | 73 | F | 20.5 | 53 |
| MSA-8 | 73 | M | 8 | 72 |
| MSA-9 | 57 | F | 8 | 35 |
| NL-1 | 69 | M | 11 | n/a |
| NL-2 | 74 | F | 3.5 | n/a |
DLB, MSA, and neuropathologically normal (NL) patients used in this study are numbered in the left-most column. The right-most column indicates the percentage of LBs and GCIs that were positive for ubiquitin staining in the cingulate cortex of DLB brains or cerebellum of MSA brains, respectively. Abbreviations: PMI, post-mortem interval; n/a, not applicable; M, male; F, female.
*This brain was used for biochemical studies only and not for the quantitative studies here.